{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T05:14:16Z","timestamp":1782623656188,"version":"3.54.5"},"reference-count":15,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A 35-year-old female presents with a prolonged activated partial thromboplastin time (aPTT) on routine testing, which is found to be due to a lupus anticoagulant. She has no medical issues, no personal or family history of thrombosis, no history of pregnancy loss, and no symptoms suggestive of an underlying rheumatologic disorder. She is a non-smoker and does not take oral contraceptives. You are asked to provide recommendations regarding the need for primary thromboprophylaxis. As you begin your literature search, you formulate the following clinical question: \u201cIn asymptomatic patients with antiphospholipid antibodies, does primary prophylaxis prevent thrombotic complications?\u201d<\/jats:p>","DOI":"10.1182\/asheducation-2009.1.247","type":"journal-article","created":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T15:35:31Z","timestamp":1260545731000},"page":"247-249","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis?"],"prefix":"10.1182","volume":"2009","author":[{"given":"Ara","family":"Metjian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111702441571900_R1","doi-asserted-by":"crossref","unstructured":"Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun. 2000;15:145\u2013151.","DOI":"10.1006\/jaut.2000.0409"},{"key":"2019111702441571900_R2","doi-asserted-by":"crossref","unstructured":"Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295\u2013306.","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"2019111702441571900_R3","doi-asserted-by":"crossref","unstructured":"Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56:2382\u20132391.","DOI":"10.1002\/art.22663"},{"key":"2019111702441571900_R4","doi-asserted-by":"crossref","unstructured":"Tarr T, Lakos G, Bhattoa HP, Shoenfeld Y, Szegedi G, Kiss E. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus. 2007;16:39\u201345.","DOI":"10.1177\/0961203306074767"},{"key":"2019111702441571900_R5","doi-asserted-by":"crossref","unstructured":"Hereng T, Lambert M, Hachulla E, et al. Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients. Lupus. 2008;17:11\u201315.","DOI":"10.1177\/0961203307084724"},{"key":"2019111702441571900_R6","doi-asserted-by":"crossref","unstructured":"Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis. 2009;68:238\u2013241.","DOI":"10.1136\/ard.2008.093013"},{"key":"2019111702441571900_R7","doi-asserted-by":"crossref","unstructured":"Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 2009;61:29\u201336.","DOI":"10.1002\/art.24232"},{"key":"2019111702441571900_R8","doi-asserted-by":"crossref","unstructured":"Tarr T, Lakos G, Bhattoa HP, et al. Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up. Clin Rev Allergy Immunol. 2007;32:131\u2013137.","DOI":"10.1007\/s12016-007-0009-8"},{"key":"2019111702441571900_R9","doi-asserted-by":"crossref","unstructured":"Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford). 2002;41:924\u2013929.","DOI":"10.1093\/rheumatology\/41.8.924"},{"key":"2019111702441571900_R10","unstructured":"Giron-Gonzalez JA, Garcia del Rio E, Rodriguez C, Rodriguez-Martorell J, Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004;31:1560\u20131567."},{"key":"2019111702441571900_R11","unstructured":"Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J Jr. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol. 1999;26:2363\u20132368."},{"key":"2019111702441571900_R12","doi-asserted-by":"crossref","unstructured":"Calvo-Alen J, Toloza SM, Fernandez M, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum. 2005;52:2060\u20132068.","DOI":"10.1002\/art.21149"},{"key":"2019111702441571900_R13","doi-asserted-by":"crossref","unstructured":"Bruce IN. \u2018Not only . . . but also\u2019: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford). 2005;44:1492\u20131502.","DOI":"10.1093\/rheumatology\/kei142"},{"key":"2019111702441571900_R14","doi-asserted-by":"crossref","unstructured":"Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med. 2000;160:2042\u20132048.","DOI":"10.1001\/archinte.160.13.2042"},{"key":"2019111702441571900_R15","doi-asserted-by":"crossref","unstructured":"Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest. 2006;129:174\u2013181.","DOI":"10.1378\/chest.129.1.174"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/247\/645535\/247_249ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/247\/645535\/247_249ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T02:44:30Z","timestamp":1573958670000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2009\/1\/247\/19843\/ASH-evidencebased-guidelines-should-asymptomatic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2009.1.247","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,1]]}}}